22.07.2021 SHOP APOTHEKE EUROPE N.V.  NL0012044747

DGAP-Adhoc: SHOP APOTHEKE EUROPE: change of forecast for the 2021 financial year


DGAP-Ad-hoc: SHOP APOTHEKE EUROPE N.V. / Key word(s): Change in Forecast
SHOP APOTHEKE EUROPE: change of forecast for the 2021 financial year

22-Jul-2021 / 20:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

SHOP APOTHEKE EUROPE: change of forecast for the 2021 financial year

Sevenum, 22 July 2021. In the context of preparing the interim financial report for the first half of 2021, the Management Board of SHOP APOTHEKE EUROPE has analysed the company's financial development and as a result has come to a new assessment of the forecast for the 2021 financial year.

Taking into account constraints in order processing capacity in connection with a tight labour market that became apparent in the course of Q2, the Management Board now expects full-year sales growth of 10 to 15 percent (previously: around 20 percent) and an adjusted EBITDA margin around break-even (previously: 2.3 to 2.8 percent). The expected Capex volume has been narrowed to around EUR 45 million (previously: 3.5 percent of sales). According to the company, the current logistics constraints are temporary and an isolated issue without impacting any of the future growth opportunities.

rikutis consulting
Thomas Schnorrenberg
Cel: +49 151 46 53 13 17
E-Mail: [email protected]

Information and Explanation of the Issuer to this News:

CEO Stefan Feltens: 'The constrained logistics capacity at this moment, is of a temporary nature and expected to be resolved over the coming months. Our long-term growth prospects are not impacted and remain fully intact. The mandatory introduction of electronic prescriptions (eRx) in Germany is around the corner, we are well-prepared and in a pole position with our digital expertise and leading SHOP APOTHEKE brand.'

Jasper Eenhorst, CFO of SHOP APOTHEKE EUROPE, explains: 'Due to the current parallel operation of two logistics centres in connection with the move to our new, largely automated, logistics facility, and continuing strong customer demand, we could not fully meet our staffing needs in Q2 and July - especially in the context of a tight labour market that became apparent in the course of Q2. We feel comfortable that we will overcome these constraints in the coming months in order to re-accelerate our growth again later this year, as reflected in our updated guidance.'

Conference Call on 23 July 2021, 11:00 CEST
The company will hold a conference call tomorrow at 11 a.m. CEST to discuss the updated forecast. Stefan Feltens, CEO, and Jasper Eenhorst, CFO, will host the call. Participants can access the call by dialing one of the numbers provided below and referencing confirmation code 8646132. Callers should dial in 5-10 minutes prior to the call time.


+49 (0)69 2222 2018

United Kingdom

+44 (0)330 336 9434

United States

+1 323-994-2093

SHOP APOTHEKE EUROPE N.V. will publish the full interim report for the first half of 2021 on 5 August 2021.


SHOP APOTHEKE EUROPE is one of Europe's leading and fastest-growing online pharmacies, currently operating in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.

Headquartered in the Dutch logistics hub of Sevenum near Venlo with locations in Cologne, Berlin, Munich, Warsaw, Milan, Paris and Tongeren, SHOP APOTHEKE EUROPE offers its customers a broad range of more than 100,000 original products at attractive prices: OTC, beauty and personal care products as well as prescription drugs, supplemented by high quality natural food and health products, low carb products and sports nutrition. Currently, more than 7 million active customers trust SHOP APOTHEKE EUROPE.

Since safe and reliable pharmaceutical advice are top priorities at SHOP APOTHEKE EUROPE, the e-pharmacy provides comprehensive pharmaceutical consulting services.

In preparation for the introduction of electronic prescriptions in Germany in summer 2021, the company will further improve the customer experience with focus on disease-specific digital medication management services following the acquisition of SMARTPATIENT in January 2021. This is a key part of SHOP APOTHEKE EUROPE's strategy to transform itself from a pure online retailer into a truly customer-centric e-pharmacy platform.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 2016 and has been part of the MDAX stock index since September 2020.


Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31
Email: [email protected]

Financial media:
Bettina Fries
Tel: +49 211 75 80 779
Email: [email protected]

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109
Email: [email protected]

Thomas Schnorrenberg
Mobile: +49 151 465 31317
Email: [email protected]


22-Jul-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Dirk Hartogweg 14
5928 LV Venlo
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1221087

End of Announcement DGAP News Service

1221087  22-Jul-2021 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 177,39 283,99 539,71 701,01 968,06 1.060,32 1.270,00
EBITDA1,2 -8,84 -12,14 -15,56 -18,58 15,20 -38,73 -25,00
EBITDA-Marge3 -4,98 -4,27 -2,88 -2,65 1,57 -3,65 -1,97
EBIT1,4 -11,64 -19,20 -28,73 -33,45 -0,87 -65,70 -52,00
EBIT-Marge5 -6,56 -6,76 -5,32 -4,77 -0,09 -6,20 -4,09
Jahresüberschuss1 -18,45 -21,36 -33,61 -36,27 -16,77 -74,19 -57,00
Netto-Marge6 -10,40 -7,52 -6,23 -5,17 -1,73 -7,00 -4,49
Cashflow1,7 -17,21 -23,24 -23,54 -30,37 17,80 11,64 19,00
Ergebnis je Aktie8 -2,03 -2,25 -2,79 -2,78 -1,17 -4,15 -3,00
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

Shop Apotheke Europe
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2AR94 85,040 Halten 1.547,67
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
106,30 0,00 0,00 -42,10
3,73 133,02 1,46 -33,14
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
0,00 0,00 0,00 14.04.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
05.05.2022 03.08.2022 31.10.2022 02.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-0,86% -21,26% -24,88% -45,73%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SHOP APOTHEKE EUROPE N.V.  ISIN: NL0012044747 können Sie bei DGAP abrufen

E-Commerce , A2AR94 , SAE , XETR:SAE